If Aricept seems not to be helping, the next step is a medical reassessment—not an automatic dose increase or medication switch. The clinician should check for expected disease progression, an incorrect dementia diagnosis, a treatable new problem, and medication risks. Aricept, the brand name for donepezil, can ease some Alzheimer's symptoms but does not stop the disease. Its benefit may appear as slower loss of abilities rather than visible improvement, so continued decline alone does not prove that it has failed.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does continued decline mean Aricept has stopped working?
- Confirm the cause of the dementia
- Review the dose, side effects, and tradeoffs
- When might memantine be considered?
- Are newer Alzheimer's treatments an option?
Does continued decline mean Aricept has stopped working?
Not necessarily. A 2018 Cochrane review found that donepezil produces small short-term benefits in cognition, daily activities, and overall clinical status. The National Institute on Aging also notes that benefits from this type of medication can fade as Alzheimer's progresses.
That makes effectiveness difficult to judge from a single bad week or memory test. A more useful review compares the person's present abilities with their condition before treatment: managing meals, dressing, holding conversations, recognizing people, or participating in familiar activities. Ask the prescriber what Aricept was expected to preserve and over what period. The practical question is not only, "Is the person improving?" It is also, "Could the medication be slowing a decline that would otherwise be faster?".
Confirm the cause of the dementia
aricept is not approved for dementia in general. The DailyMed prescribing label identifies it as a treatment for dementia of the Alzheimer's type. An apparent lack of response therefore deserves a review of the diagnosis before another Alzheimer's medication is added.
A new or sudden change is especially important. The National Institute on Aging says worsening memory, behavior, or alertness can reflect infection, medication effects, disturbed sleep, stroke, a tumor, or another form of dementia. These possibilities require medical assessment rather than being dismissed as routine progression. Prepare a brief timeline for the appointment:.
- Note whether the change was gradual or sudden.
- Record changes in alertness, sleep, behavior, appetite, and daily abilities.
- List all medicines and recent medication changes.
- Identify missed Aricept doses or problems taking it consistently.
- Bring observations from someone who sees the person regularly.
Review the dose, side effects, and tradeoffs
A higher dose is not a risk-free default. The DailyMed label reports more nausea and vomiting with 23 milligrams than with 10 milligrams. It also warns about slow heart rate or heart block, fainting, and weight loss. The prescriber should weigh any retained function against side effects and the person's other medical conditions.
Report nausea, vomiting, weight loss, fainting, or a noticeable decline in eating. A sudden loss of alertness or abrupt behavioral change should prompt timely medical assessment. Do not judge the medication only by a memory score. Ask the clinician to review cognition, daily function, side effects, caregiver observations, and the original reason for prescribing Aricept before deciding whether to continue, adjust, or replace it.
When might memantine be considered?
For moderate-to-severe Alzheimer's disease, memantine may be prescribed alone or with a cholinesterase inhibitor such as donepezil. It works differently and may help preserve some daily function longer, but it does not cure Alzheimer's, according to National Institute on Aging treatment guidance.
Memantine is therefore a stage-specific discussion, not proof that Aricept failed. Ask whether the person's current stage and diagnosis fit its use, what changes the clinician expects, and how benefits and side effects will be monitored.
Are newer Alzheimer's treatments an option?
Lecanemab and donanemab are options only for confirmed Alzheimer's disease at the mild cognitive impairment or mild dementia stage. They are not treatments for established moderate or severe dementia, and they require evidence of amyloid disease in the brain. These medicines target the disease process rather than simply treating symptoms, but their average trial benefits were modest. They also carry meaningful risks.
The FDA prescribing information for lecanemab warns about amyloid-related imaging abnormalities, or ARIA—brain swelling or bleeding that can rarely become serious or fatal. Treatment involves baseline and scheduled MRI monitoring and assessment of ApoE ε4-related risk. Medicare access also has specific conditions. CMS requires mild cognitive impairment or mild Alzheimer's dementia, documented brain amyloid, and treatment by a clinician participating in a qualifying registry with follow-up care. Before pursuing treatment, ask whether the diagnosis, disease stage, amyloid testing, MRI monitoring, and registry requirements all apply.
